Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Off-Label Teduglutide Therapy in Non-intestinal Failure Patients with Chronic Malabsorption.

George AT, Li BH, Carroll RE.

Dig Dis Sci. 2019 Feb 7. doi: 10.1007/s10620-019-5473-5. [Epub ahead of print]

PMID:
30730014
2.

Single-Center Experience with the Use of Teduglutide in Adult Patients with Short Bowel Syndrome.

Lam K, Schwartz L, Batisti J, Iyer KR.

JPEN J Parenter Enteral Nutr. 2018 Jan;42(1):225-230. doi: 10.1002/jpen.1011. Epub 2017 Dec 13.

PMID:
29505151
3.

Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.

Kochar B, Long MD, Shelton E, Young L, Farraye FA, Yajnik V, Herfarth H.

J Clin Gastroenterol. 2017 Jul;51(6):508-511. doi: 10.1097/MCG.0000000000000604.

4.

Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome.

Tappenden KA, Edelman J, Joelsson B.

J Clin Gastroenterol. 2013 Aug;47(7):602-7. doi: 10.1097/MCG.0b013e3182828f57.

PMID:
23426461
5.

Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome.

Jeppesen PB.

JPEN J Parenter Enteral Nutr. 2014 May;38(1 Suppl):45S-52S. doi: 10.1177/0148607114526241. Epub 2014 Mar 10. Review.

PMID:
24615689
6.

Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome.

Carter BA, Cohran VC, Cole CR, Corkins MR, Dimmitt RA, Duggan C, Hill S, Horslen S, Lim JD, Mercer DF, Merritt RJ, Nichol PF, Sigurdsson L, Teitelbaum DH, Thompson J, Vanderpool C, Vaughan JF, Li B, Youssef NN, Venick RS, Kocoshis SA.

J Pediatr. 2017 Feb;181:102-111.e5. doi: 10.1016/j.jpeds.2016.10.027. Epub 2016 Nov 15.

7.

Experience with teduglutide treatment for short bowel syndrome in clinical practice.

Pevny S, Maasberg S, Rieger A, Karber M, Blüthner E, Knappe-Drzikova B, Thurmann D, Büttner J, Weylandt KH, Wiedenmann B, Müller VA, Bläker H, Pascher A, Pape UF.

Clin Nutr. 2018 Aug 2. pii: S0261-5614(18)31243-3. doi: 10.1016/j.clnu.2018.07.030. [Epub ahead of print]

PMID:
30145039
8.

Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.

Jeppesen PB, Pertkiewicz M, Forbes A, Pironi L, Gabe SM, Joly F, Messing B, Loth S, Youssef NN, Heinze H, Berghöfer P.

Clin Nutr. 2013 Oct;32(5):713-21. doi: 10.1016/j.clnu.2013.03.016. Epub 2013 Mar 28.

PMID:
23587733
9.

Increased intestinal absorption in the era of teduglutide and its impact on management strategies in patients with short bowel syndrome-associated intestinal failure.

Seidner DL, Schwartz LK, Winkler MF, Jeejeebhoy K, Boullata JI, Tappenden KA.

JPEN J Parenter Enteral Nutr. 2013 Mar;37(2):201-11. doi: 10.1177/0148607112472906. Epub 2013 Jan 23.

PMID:
23343999
11.

Long-Term Therapy With Teduglutide in Parenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series.

Ukleja A, To C, Alvarez A, Lara LF.

JPEN J Parenter Enteral Nutr. 2018 May;42(4):821-825. doi: 10.1002/jpen.1149. Epub 2018 Mar 30.

PMID:
29603279
12.

Teduglutide for the treatment of short bowel syndrome - a safety evaluation.

Kochar B, Herfarth HH.

Expert Opin Drug Saf. 2018 Jul;17(7):733-739. doi: 10.1080/14740338.2018.1483332. Epub 2018 Jun 8. Review.

PMID:
29848084
13.

Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome.

Iyer KR, Kunecki M, Boullata JI, Fujioka K, Joly F, Gabe S, Pape UF, Schneider SM, Virgili Casas MN, Ziegler TR, Li B, Youssef NN, Jeppesen PB.

JPEN J Parenter Enteral Nutr. 2017 Aug;41(6):946-951. doi: 10.1177/0148607116680791. Epub 2016 Nov 23.

14.

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.

Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ.

Gut. 2011 Jul;60(7):902-14. doi: 10.1136/gut.2010.218271. Epub 2011 Feb 11.

15.

Short bowel syndrome: highlights of patient management, quality of life, and survival.

Kelly DG, Tappenden KA, Winkler MF.

JPEN J Parenter Enteral Nutr. 2014 May;38(4):427-37. doi: 10.1177/0148607113512678. Epub 2013 Nov 18. Review.

PMID:
24247092
16.

Clinical Management of Patients With Parenteral Nutrition-Dependent Short Bowel Syndrome During Teduglutide Therapy.

Compher C, Boullata JI, Pickett-Blakely O, Schiavone P, Stoner N, Kinosian BP.

JPEN J Parenter Enteral Nutr. 2016 Nov;40(8):1183-1190. Epub 2015 Jun 25.

PMID:
26111832
17.

Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.

Jeppesen PB, Gabe SM, Seidner DL, Lee HM, Olivier C.

Gastroenterology. 2018 Mar;154(4):874-885. doi: 10.1053/j.gastro.2017.11.023. Epub 2017 Nov 22.

18.

Teduglutide-Stimulated Intestinal Adaptation Is Complemented and Synergistically Enhanced by Partial Enteral Nutrition in a Neonatal Piglet Model of Short Bowel Syndrome.

Naberhuis JK, Deutsch AS, Tappenden KA.

JPEN J Parenter Enteral Nutr. 2017 Jul;41(5):853-865. doi: 10.1177/0148607115602891. Epub 2015 Aug 24.

PMID:
26304601
19.

Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome.

Jeppesen PB.

Therap Adv Gastroenterol. 2012 May;5(3):159-71. doi: 10.1177/1756283X11436318.

20.

Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure.

O'Keefe SJ, Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B.

Clin Gastroenterol Hepatol. 2013 Jul;11(7):815-23.e1-3. doi: 10.1016/j.cgh.2012.12.029. Epub 2013 Jan 17.

PMID:
23333663

Supplemental Content

Support Center